Inventia Life Science, a biomedical research company, has raised A$35 million ($25 million) in a Series B funding round, led by Blackbird Ventures, to market its cell culture platform globally and grow its team, the company said in a statement on Thursday.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
